Lomefloxacin Chemical Properties

Melting point:

239-240 C

Boiling point:

542.7±50.0 °C(Predicted)

Density 

1.342±0.06 g/cm3(Predicted)

storage temp. 

Keep in dark place,Sealed in dry,Store in freezer, under -20°C

solubility 

DMSO (Slightly), Methanol (Slightly, Heated, Sonicated)

form 

Solid

pka

-0.25±0.20(Predicted)

color 

Pale Yellow to Light Yellow

CAS DataBase Reference

98079-51-7(CAS DataBase Reference)

EPA Substance Registry System

3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo- (98079-51-7)

Safety Information

Hazard Codes 

Xn,Xi

Risk Statements 

22-36/37/38

Safety Statements 

26-36

WGK Germany 

3

RTECS 

VB1997500

HS Code 

29419000

Toxicity

LD50 in mice (mg/kg): 245.6 i.v.; >4000 orally (Itoh)

MSDS

• Language:English Provider:1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid

Lomefloxacin Usage And Synthesis

Description

Lomefloxacin is a kind of fluoroquinolone antibiotics used for the treatment of bacterial infections such as bronchitis and urinary tract infection. It can also used to prevent the urinary tract infections prior surgery. It has bactericidal effect against a wide range of gram-negative and gram-positive organisms. It takes effect through interfering with the normal function of the bacteria enzyme DNA gyrase and topoisomerase IV, further inhibiting the transcription and replication of bacterial DNA. This effect results in strand breakage of bacterial chromosome, supercoiling and resealing, further causing bacteria death.

References

https://en.wikipedia.org/wiki/Lomefloxacin
https://www.drugbank.ca/drugs/DB00978

Description

Lomefloxacin is a once-daily, third-generation quinolone antibiotic useful in the treatment of bacterial infections. The new fluorinated quinolone does not interfere with the metabolism of theophylline; it is efficacious against pathogens resistant to cephalosporins, penicillins and aminoglycosides.

Chemical Properties

colorless Needles

Originator

Hokuriku Seiyaku (Japan)

Uses

Anti bacterial.

Definition

ChEBI: A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.

Manufacturing Process

A mixture of 1.00 g of 1-ethyl-6,7,8-trifluoro-1,4-dihydro-4-oxoquinoline-3- carboxylic acid, 1.10 g of 2-methylpiperazine and 10 ml of pyridine was heated for 15 minutes under reflux. The reaction mixture was evaporated and methanol was added to the residue. The precipitate was filtered and recrystallized from ethanol to give 0.36 g of the 1-ethyl-6,8-difluoro-1,4- dihydro-7-(3-methyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid as colorless needles, melting point 239.0-240.5°C.
By the usual manner the hydrochloride was prepared and recrystallized from water as colorless needles, melting point 290-300°C (decomp.).

brand name

Uniquin

Therapeutic Function

Antibacterial

Pharmaceutical Applications

A difluoropiperazinyl quinolone formulated as the hydrochloride salt for oral administration. The in-vitro activity is very similar to that of norfloxacin . It is active against Enterobacteriaceae and fastidious Gram-negative bacilli, including L. pneumophila. Activity against Campylobacter spp., Ps. aeruginosa, Acinetobacter and Chlamydia spp. is poor. It has reduced activity against staphylococci and poor activity against streptococci, L. monocytogenes, anaerobes and Mycobacterium spp.
A 400 mg oral dose achieves a concentration of 3–5 mg/L after 1–1.5 h. In escalating oral doses of 100, 400 and 800 mg to volunteers, the AUC was essentially proportional to the dosage, the mean plasma concentrations following 100, 400 and 800 mg doses being approximately 1.1, 4.7 and 7.5 mg/L, respectively.
Several metabolites have been described, accounting for <5% of the oral dose. Elimination occurs principally via the kidneys and 50–70% of a dose appears in the urine over 24 h. In patients with impaired renal function given 400 mg orally, the apparent elimination half-life ranged from 8 to 44 h, depending on the degree of renal failure. Non-renal clearance was also impaired, but there was no significant change in other pharmacokinetic parameters. The daily dosage (400 mg) should be reduced to 280 mg when the creatinine clearance falls below 30 mL/min. Hemodialysis has no effect on the plasma concentration. The effect of lomefloxacin on the plasma concentration of theophylline is clinically insignificant and no dosage adjustment is required.
The main adverse event is phototoxicity; other adverse events (mainly diarrhea, abdominal pain, skin reactions, dizziness, headache and insomnia) occur in about 10% of patients.
It is chiefly used in urinary tract infection, but is no longer widely available.

Clinical Use

1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid (Maxaquin) is adifluorinated quinolone with a longer elimination half-life(7–8 hours) than other members of its class. It is the onlyquinolone for which once-daily oral dosing suffices. The oralbioavailability of lomefloxacin is estimated to be 95% to98%. Food slows, but does not prevent, its oral absorption.The extent of biotransformation of lomefloxacin is only about5%, and high concentrations of unchanged drug, rangingfrom 60% to 80%, are excreted in the urine. The comparativelylong half-life of lomefloxacin is apparently because ofits excellent tissue distribution and renal reabsorption and not because of plasma protein binding (only ～10%) or enterohepaticrecycling (biliary excretion is estimated to be ～10%).
Lomefloxacin has been approved for two primary indications. First, it is indicated for acute bacterial exacerbations of chronic bronchitis caused by H. influenzae or Moraxella (Branhamella) catarrhalis, but not if Streptococcus pneumoniae is the causative organism. Second, it is used for prophylaxis of infection following transurethral surgery. Lomefloxacin also finds application in the treatment of acute cystitis and chronic urinary tract infections caused by Gram-negative bacilli.

Lomefloxacin(98079-51-7)Related Product Information

• Methylparaben
• Paraquat dichloride
• Dihydromyrcenol
• N-Aminoethylpiperazine
• (2-Methoxyethyl)benzene
• 1-Methylpiperazine
• Kresoxim-methyl
• Methanol
• Basic Violet 1
• Acetonitrile
• Methyl acetate
• Methyl acrylate
• Methyl
• LOMEFLOXACIN HCL,LOMEFLOXACIN HYDROCHLORIDE
• 2-Butanone
• Sparfloxacin
• Orbifloxacin
• Sparfloxacin